Revenue solid, but PAT crushed by taxes and new venture drag
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met India market-outperformance guidance (100 bps); EBITDA margin held. But US guidance softened from 'high single digit' to 'high single-digit to mid', and Daman OAI unplanned regulatory overhang.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Solid revenue growth (11% YoY) and India outperformance (100 bps above market) offset by PAT collapse (-22%, tax-driven) and Daman OAI regulatory risk (45% of US revenue). Core pharma business executing well, but new ventures (CDMO ₹60 Cr/Q burn, MedTech integration delays) are dragging consolidated results. US business volume-challenged, relying only on forex tailwinds.
₹3740.2 Cr
Revenue · +10.9% YoY₹521 Cr
Reported PAT · −22% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
India growth 100 bps above market (IQVIA basis)
METCompany 13.2% vs IPM 12.2% = 100 bps outperformance
EBITDA margin held at 20.5%
METQ1 EBITDA margin 20.5% reported
PAT decline is purely taxation-driven
METConsolidated tax rate 30-32% vs prior 27-28% stand-alone; new venture losses (Enzene CDMO ₹60 Cr/Q opex)
US business in high single digit growth
OVERSTATEDInt'l revenue (incl. US) +16% but forex-flattered; constant-currency showing softness; no volume growth
Daman facility OAI has no business impact, supplies uninterrupted
MISS45% of US revenue at risk; management claims no disruption but regulatory risk material
Earnings quality
What changed since the last call
US guidance softened
DowngradePrior 'high single digit'; now 'high single-digit to mid'. Reflects volume weakness (no growth in recent launches) and Daman OAI risk mitigation in tone.
Int'l guidance arguably downgraded
DowngradePrior 'higher teens growth'; now emphasized 'sustainable double digit.' Q1 delivered 16%, so guidance not formally withdrawn but tone suggests lower expectations going forward.
India guidance effectively maintained
NeutralPrior 100-150 bps above market; delivered 100 bps in Q1, targeting ~12% for FY27 (still 100 bps above market growth). Brands +12%, Trade Generics flattish as expected.
Occlutech profitability timeline extended
DowngradePrior target 10% margins 'in near term'; now guidance 7-8% EBITDA margin improvement YoY over 3-4 years, with Q1 integration only starting (deal closed mid-July). Breakeven shifted from year 1 to year 3.
CDMO U.S. revenue expectations clarified
NeutralNo revenue yet (operational since Nov 2025). Management expects USD 25-30M annualized breakeven (not FY27, not FY27.5, but FY28). Long cycle, lumpy pipeline.
The Q&A
Analysts pressed hard on Trade Generics slowdown, CDMO unit economics, Daman OAI supply risk, and US volume trajectory. Management held up reasonably (transparent on cost drivers, tax headwinds, Daman confidence), but deflected on precise CDMO pipeline visibility and withheld exact Daman ANDA count. Tone was patient but defensive on near-term headwinds.
India growth drivers — Saion Mukherjee, Nomura
AnsweredYes, Trade Generics flattish; cost inflation from 1,200 MRs added, Enzene CDMO opex, currency conversion 10% higher than prior year. Brands +12%.
Denosumab biosimilar status — Sandeep Kumar, Clindus
PartialDelayed, pushed off by at least few months from prior goal date. No new timeline given.
India biosimilars portfolio — Amlan Jyoti Das, JPMorgan
Answered₹150 Cr annual sales, margins improved via backward integration. Part of India revenue.
Trade Generics recovery timeline — Kunal Dhamesha, Macquarie
PartialStrategic discipline on DSOs and pricing; expect recovery in coming quarters. Jan-June higher single digit growth.
CDMO unit economics — Kunal Dhamesha, Macquarie
PartialUSD 25-30M annualized (confusing start, then corrected); depends on project mix and biotech funding cycles. Decent pipeline but lumpy.
Occlutech margin guidance — Amlan Jyoti Das, JPMorgan
Answered7-8% EBITDA margin improvement YoY; target full guidance over 3-4 years due to integration delays (closed mid-July).
Daman OAI revenue exposure — Kunal Dhamesha, Macquarie
Partial45% exposure confirmed. Pending ANDA count withheld; said 'we'll come back to it'.
India M&A and MedTech strategy — Kunal Randeria, Axis
AnsweredNo acquisitions planned right now. Very early stage ramp-up; no need to acquire.
CEO hiring timeline — Abdulkader Puranwala, ICICI
PartialSearching actively, expected to be in place by next quarterly call. Critical hire, can't hurry.
US semaglutide benefit — Tushar Manudhane, Motilal Oswal
AnsweredVery small right now. But Alkem is among top 3 in semaglutide generics.
US constant-currency weakness — Rashmi Shetty, Dolat Capital
AnsweredPrice erosion has bottomed out. No volume growth from recent launches. Only forex helping. US challenging.
US guidance revision — Rashmi Shetty, Dolat Capital
AnsweredHigh single-digit to mid. Daman OAI not expected to impact FY27, resolved in 6-12 months.
Guidance
India FY27 ~12% growth (on track, 100 bps above market)
HighBrands +12% delivered Q1, Trade Generics recovery expected. Market growth ~11%, company target 12% = 100 bps outperformance maintained
US FY27 mid-to-high single digit (forex-aided)
MediumSoftened from prior 'high single digit'. Daman OAI risk acknowledged but no impact expected FY27; price erosion bottomed; no volume growth
International (ROW) FY27 sustainable double-digit
MediumPrior 'higher teens', now 'double digit sustainable'. Q1 delivered 16%. Management says 'more than sustainable' but no numeric upgrade
Gross margin 66.5-67% (balance of FY27)
MediumMaintained. Q1 benefited from mix (lower Trade Generics, higher prescription) and currency. API price increases expected to offset going forward
EBITDA margin 20.5% (flat implied for FY27)
MediumNot explicitly guided but Q1 held. New-venture (CDMO, MedTech) losses will be absorbed at consolidation level
CDMO Enzene: capex required for scale-up once revenue ramps (not FY27)
LowManagement flagged future capex need for CDMO as it scales to USD 30M+ annualized. No FY27 capex impact expected
Risks the call surfaced
Regulatory (Daman OAI)
HighDaman facility received OAI; represents 45% of US revenue. Management claims no supply impact and confident on 6-12 month resolution, but regulatory risk is material near-term.
Volume Growth (US Market)
MediumUS business showing no volume growth from launches in last 12-24 months; only forex and price anchoring contributing. Constant-currency revenue soft. Indicates market saturation or launch execution issues.
CDMO Execution Risk
MediumUS CDMO burning ₹60 Cr/quarter with zero revenue yet (operational since Nov 2025). Breakeven requires USD 25-30M annualized, expected by FY28. Lumpy project cycle and biotech funding dependency.
MedTech Integration Risk
MediumOcclutech acquired mid-July (after Q1); integration just started. Prior guidance ~10% margins 'in near term' now pushed to 7-8% improvement YoY over 3-4 years. Small ortho business (₹50 Cr yearly) also integrating.
Tax Rate Headwind
MediumConsolidated tax rate 30-32% vs prior stand-alone guidance 27-28%. Driven by new-venture losses (Enzene, MedTech) where deferred tax assets not recognized. Masks core pharma profitability.
Trade Generics Slowdown
LowTrade Generics flattish YoY, dragging India average to 10.3% (vs branded +12%). Management attributes to competition intensification and intentional DSO discipline. Recovery to single-digit growth acceptable to management, not double-digit.
Management
Score 7/10. Transparent on cost drivers (MR additions, currency, Enzene opex). Clear on segmental performance. But vague on CDMO pipeline specifics and withheld Daman ANDA count. India track record strong (100 bps outperformance delivered vs guided). Trade Generics and US volume challenges under-delivered. New ventures on early-stage timelines (CDMO, MedTech).
1 · Q2-Q3 FY27
Daman OAI regulatory resolution, corrective actions completion
2 · H2 FY27
Occlutech India integration; MedTech margin recovery begins
3 · FY27 end
Denosumab US biosimilar approval (delayed from prior target)
US business volume-challenged, relying only on forex tailwinds.
Alkem Q1FY27: consolidated PAT down 22% YoY on tax-regime reset, PBT nearly flat
PAT -21.99% YoY · revenue +10.95% · margins compressing
₹3,740.15 Cr
+10.95% YoY
₹520.98 Cr
-21.99% YoY
13.38%
-5.7pp YoY
₹43.49
Alkem's consolidated PAT fell 22.0% YoY to Rs520.98 Cr in Q1 FY27 (quarter ended 30 June 2026), even as revenue from operations grew a healthy 10.95% YoY to Rs3,740.15 Cr and consolidated PBT was essentially flat (Rs771.99 Cr vs Rs771.01 Cr a year earlier, +0.1%). The gap between flat pretax profit and a sharply lower bottom line is explained almost entirely by tax: the effective tax rate jumped to 32.5% this quarter from 13.3% in Q1 FY26, after the company moved to the new tax regime under Section 115BAA of the Income-tax Act (Note 4) - deferred tax is now recognised at the new regime's enacted rates, ending the more favourable MAT-credit treatment used earlier. Standalone PAT of Rs569.98 Cr was down a smaller 13.1% YoY on 12.5% revenue growth to Rs2,667.73 Cr - a divergence of more than 3 points from the consolidated decline, stemming from subsidiary-level tax, NCI and associate dynamics that don't touch the parent-only numbers. Neither statement carries an exceptional item this quarter; a year ago the consolidated result had booked a small Rs12.93 Cr one-off gain from the Indore facility sale, so the adjusted YoY PAT decline (~20.5%) is only marginally softer than the reported -22.0%.
Q1 FY-2027 vs prior quarters
Margins compressed on a YoY basis even before the tax effect. Core pre-exceptional profitability (PBT before exceptional items as a share of total income) slipped to 19.83% from 21.62% a year ago, as employee benefits expense rose 16.7% YoY (Rs808.90 Cr vs Rs693.25 Cr) and finance costs nearly doubled (+56.6% YoY, Rs46.62 Cr vs Rs29.78 Cr), both outpacing the 10.95% topline growth. Net margin (PAT/total income) fell to 13.4% from 19.0% YoY. Sequentially, PAT more than doubled (+107.5% QoQ) against Q4 FY26's Rs251.11 Cr, but that base was itself depressed by a Rs134.97 Cr net exceptional charge (a Rs74.7 Cr real-estate impairment provision plus a Rs60.27 Cr gratuity/leave-encashment liability under the new Labour Codes) - so the QoQ jump is a base-effect artefact rather than fresh operating momentum and should not be read as a trend.
The stock went into the print at ₹5,417, down 5.1% over the past month of trading.
What the summary numbers don't show
EPS: consolidated Rs43.49 (vs Rs55.56 YoY, Rs19.77 QoQ) — standalone Rs47.67 (vs Rs52.04 YoY, Rs18.16 QoQ).
Alkem Laboratories is projecting continued strong growth in FY27, with the India business expected to grow 100-150 basis points above market rates, driven by key therapies and new launches like semaglutide. The US business is anticipated to achieve high single-digit growth on a dollar-to-dollar basis, potentially boost
— This quarter: met
We could not find reliable analyst consensus estimates specifically previewing this Q1 FY27 print, so the vs-street read is unknown rather than assumed. Against management's own FY27 outlook from the May 2026 call - a 20-21% margin target, India growth 100-150bps above market, US high-single-digit dollar growth, and ROW higher-teens growth - this filing (single-segment disclosure, no India/US/ROW split) only lets us check the margin line: core pre-exceptional margin of ~19.8% sits just under the guided band, so the quarter reads as broadly on track rather than a clear beat or miss. Alkem issued no accompanying press-release commentary with this filing (none extracted for this result), so there is no fresh management framing to reconcile against the numbers. Two corporate developments bracket this print: Alkem Medtech completed its majority-stake acquisition of Switzerland's Occlutech Holding AG on 16 July 2026 (Note 5) - after the reporting quarter, so it has no impact on these numbers but enters consolidation from Q2 FY27; and a company facility was placed under USFDA OAI status on 6 August 2026, a regulatory flag that doesn't show up in this quarter's P&L but is worth tracking for supply continuity.
W1
FY27 margin trajectory vs management's 20-21% target - core PBT margin was ~19.8% this quarter, still just under the guided band.
W2
Whether the ~32.5% effective tax rate (new 115BAA regime) persists through FY27 or eases as the transition beds in.
W3
Occlutech integration entering consolidation from Q2 FY27, and remediation status/impact from the 6 Aug 2026 USFDA OAI flag at an Alkem facility.
India Outperformance Overshadowed by PAT Collapse
Revenue growth hit guidance targets with India delivering 100 basis points of outperformance. But consolidated profit collapsed 22%, a hit entirely driven by new-venture losses and a tax-rate spike. Core pharma is holding up.
₹3,740 Cr
+10.9% YoY, India ₹2,497 Cr
20.5%
Flat YoY, held guidance
₹521 Cr
-22% YoY, NPM 13.4%
100 bps
13.2% vs IPM 12.2%, on track
Alkem delivered solid revenue growth and hit its India market-outperformance target in Q1 FY-2027. But the quarter's real story lies in a paradox: EBITDA margin held flat at 20.5%, yet reported profit collapsed 22%. The gap is structural, not operational — and it defines near-term risk.
Where the profit went
Reported PAT of ₹521 crore would look fine if not for two headwinds. First, the consolidated tax rate spiked to 30–32%, up from a prior stand-alone 27–28%. Why? Because new ventures — the US-based CDMO (Enzene) and MedTech assets — are reporting losses, and management is not recognizing deferred tax assets on those entities. Second, the CDMO is burning ₹60 crore per quarter with zero revenue yet (operational since November 2025). This structural drag is why core-business EBITDA margin sat flat while profit tanked. Strip out the new-venture losses and the tax-rate hit, and core pharma's underlying profitability is consistent.
At consolidated level, it will be in the range of 30–32% because entities like Enzene in U.S. are reporting losses and we're not creating DTA on those entities.
What management claimed — and what held up
India will outperform market by 100 bps
SupportedDelivered 13.2% vs IPM 12.2% = 100 bps outperformance
EBITDA margin will hold at 20.5%
SupportedQ1 EBITDA margin held at 20.5%, flat YoY
US business in high single-digit growth
OverstatedIntl revenue +16% but forex-flattered; constant-currency soft, zero volume growth from recent launches
Daman facility OAI has no business impact, supplies uninterrupted
ContradictedFacility under OAI; 45% of US revenue at risk. Regulatory risk material despite management confidence.
What changed on this call
The US guidance softened. Prior calls promised 'high single-digit' growth; this time management revised to 'high single-digit to mid', citing volume weakness and Daman OAI headwinds (though they claim no FY-2027 impact). Occlutech (MedTech, acquired mid-July) saw its margin timeline extended: original guidance of ~10% margins 'in the near term' has now become 7–8% EBITDA improvement 'over 3–4 years', a realistic reset but a downgrade in tone. India guidance held steady — 100 bps outperformance remains on track, with branded generics +12% and Trade Generics flattish by design (DSO discipline for ROCE). The CDMO breakeven target is FY-2028 at USD 25–30 million annualized, not earlier.
India market outperformance (100 bps) delivered on track
EBITDA margin held at 20.5% despite new-venture drag
7 India biosimilars generating ₹150 Cr/year sales with improving margins
Reported PAT down 22% YoY despite EBITDA margin held — structural tax and new-venture hit
Daman facility under OAI — 45% of US revenue at regulatory risk, 6–12 month resolution uncertain
CDMO burning ₹60 Cr/Q with zero revenue; breakeven FY-2028 at USD 25–30M annualized
US business volume-less, relying only on forex tailwinds and price anchoring
Consolidated tax rate artificially elevated (30–32% vs 27–28%); masks underlying core profitability
Risks, ranked by how much they should concern a holder
Daman OAI — regulatory overhang on 45% of US revenue
HighFacility received OAI; management claims no supply interruption and resolution in 6–12 months. But this is a material regulatory risk not yet manifested in numbers. If enforcement escalates, US profitability could take a step down.
CDMO execution — ₹60 Cr/Q burn, zero revenue yet
MediumOperational since Nov 2025. Breakeven requires USD 25–30M annualized by FY-2028. Biotech is lumpy and long-cycle. If pipeline dries up or biotech funding freezes, CDMO could become a permanent drag.
US volume growth absent — forex only
MediumRecent launches (last 12–24 months) are not gaining traction. Management admits 'no volume growth', only currency and price anchoring. If forex reverses and volume stays flat, US growth disappears.
Consolidated tax rate artificially high (30–32% vs 27–28%)
MediumNew-venture losses (DTA not recognized) inflate consolidated tax. Masks true core-pharma PAT. As new ventures mature, tax rate should normalize, but near-term reported PAT is suppressed.
MedTech integration delays — Occlutech margin timeline extended
MediumPrior guidance 10% margins 'near term'; now 7–8% improvement over 3–4 years. Deal closed mid-July; integration just started. Cost overruns or lower synergies could stretch timeline further.
Trade Generics slowdown — strategic but real
LowFlattish YoY growth. Management is intentionally holding DSO discipline for ROCE; recovery to single digits acceptable. Not a turnaround risk, but a headwind on India growth mix.
How the street is positioned
The stock is oversold near-term. At ₹5,400, it sits below its 20-day, 50-day, and 200-day moving averages (₹5,571, ₹5,537, ₹5,544), and the RSI of 28.6 signals oversold conditions. The stock is 8.99% below its all-time high and 6.4% above its 52-week low — so downside from fundamental weakness is limited, but upside is not yet priced in. The post-result price reaction was muted: day 1 saw a +0.11% move, and by day 3 the gain had settled to +0.27%. This lack of enthusiasm suggests the market is taking a wait-and-see stance on Daman OAI resolution and new-venture execution.
Institutional positioning is mixed. Domestic institutions (DII) are adding gently (up 1.23 percentage points quarter-on-quarter to 22.63%), and mutual funds are visible in block deals at ₹5,200 — suggesting some tactically astute buyers are opportunistic on oversold levels. But foreign institutions (FII) are flat (10.42%, up just 0.26pp), which usually signals hesitation on emerging-market pharma amid macro uncertainty. Promoters have trimmed 1.5 percentage points to 49.70%, and insider block sales are visible at ₹5,200, a mild negative signal. Taken together: the market is not panicking, but it's not excited either. Valuation is attractive near-term, but conviction will return only when Daman is resolved and CDMO shows material revenue.
What to watch next
1 · Daman OAI regulatory resolution (Q2–Q3 FY-2027)
Management is confident of resolution in 6–12 months. This is the single biggest overhang. If resolved cleanly with no supply disruption, it's an immediate confidence builder for the US business.
2 · CDMO revenue inflection (H2 FY-2027 onward)
Management expects USD 25–30M annualized revenue by FY-2028. Q2 and Q3 are key quarters to see if the 'decent pipeline' of biotech clients begins to translate into orders. Any material win is re-rating material.
3 · Occlutech India integration progress (H2 FY-2027)
MedTech deal closed mid-July (post-Q1). Integration ramp and early margin metrics (targeting ₹400 Cr sales for 8.5 months, breakeven EBITDA) will define credibility of the 7–8% margin path over 3–4 years.
4 · US volume recovery or continued stalling (Next 2–3 quarters)
Recent launches are not gaining traction. If constant-currency growth remains flat, the US story deteriorates materially. Watch for management guidance on new launches and their expected ramp.
Alkem's core pharma business is executing well. India outperformance is delivered, EBITDA margin is held, and the chronic-disease portfolio is firing on all cylinders. But consolidated results are obscured by new-venture losses and a temporary tax-rate spike. The market's muted reaction reflects this ambiguity: the stock is oversold on near-term weakness, but upside is capped until Daman OAI is resolved and CDMO shows revenue traction.
This is steady execution, not a step-change. The stock is a hold for now — valuation is reasonable for a holding company with core pharma plus optionality on new ventures, but conviction requires catalysts. For quarter-to-quarter tracking, watch the adjusted core-pharma PAT (or EBITDA), not the reported number. That's where the real earnings power lies.
Mid-year tracking: margin defense amid FDA headwinds
With the FDA inspection fallout still settling, focus turns to whether Alkem can sustain its US momentum and deliver on FY27 guidance — Q1 is a key read for the growth and margin story.
What to Expect
~₹550-600 Cr
Mid-year typical; US segment the swing factor — 40%+ of revenue
~20-21%
In-line with FY27 guidance; Medtech losses offset by core generics strength
~₹120-135 Cr
Normal run-rate; prior year benefited from tax wins (not repeating)
A strong Q1 print would show: revenue growth in the low double digits YoY (12-15% range), margins holding the 20-21% band despite Medtech drag, and credible FDA remediation clarity (timeline and confidence on the April-May OAI observations). A weak print would flag: revenue miss (sub-10% growth), margin compression below 20%, vague FDA commentary, or binding cautions on production capacity or shipment continuity.
On Track?
FY26 ended at ₹2,308 Cr revenue; FY27 guidance is embedded in the 20-21% EBITDA margin signal, implying steady growth with operational leverage. Q1 is mid-year and should confirm whether the US rebound (which drove Q4 FY26) is sustaining. The Occlutech acquisition (closed July 2026) is non-consolidated for now; Medtech losses (₹40-50 Cr annually through FY28) are a known drag on reported margin. Watch for cash deployment and integration ramp in Q1.
What the Street Says
Since Last Quarter
1 · FDA OAI Status (Aug 6) — Amaliya, Daman
Facility received Official Action Indicated status following April 20–May 1, 2026 inspection. Seven FDA 483 observations noted on Form FDA 483. OAI status means the FDA will halt new ANDA approvals until observations are remediated. Material compliance risk — no timeline or severity disclosed yet; this dominates the pre-result narrative and will be the first Q&A on the call.
2 · Occlutech Acquisition Completed (Jul 17)
Wholly-owned Alkem Medtech acquired Occlutech Holding AG (Swiss medical device company). Capex and losses of ₹40-50 Cr annually through FY27; targeting Medtech breakeven by FY28. Q1 consolidation will reflect the first month of Occlutech contribution.
3 · Semaglutide Launch (Jun 2) — Specialty Play
First-to-market in India: single-shot pre-filled syringes at ₹350. Addresses diabetes/obesity space — large TAM but nascent penetration. Q1 revenue contribution minimal; upside story for FY27-FY28 as awareness ramps.
4 · Tax Win ₹660.77 Cr (Jul 1) — Non-Repeating
Favorable orders-in-appeal from CoIT Mumbai (AY 2018-19 to 2022-23) for disallowance deletions. One-time positive; reduces effective tax rate for the reported P&L but won't repeat. Mark as non-operating.
5 · Management Reshuffle (Aug 3 & Jul 23)
Rajpal Singh Rana (30+ years marketing/sales) appointed to senior management (Aug 3). Dr. Jitendra Singh Huda resigned seeking other opportunities (Jul 23). Scale-routine, but signals leadership changes — watch for strategy commentary on the call.
6 · Merger/Amalgamation Scheme Approval (Aug 17)
Shareholder meeting Aug 17 to approve scheme of amalgamation; details sparse. Likely Medtech consolidation; await disclosures for impact clarity.
On Result Day (Aug 14)
1 · FDA Remediation Plan & Timelines
Management must address Amaliya OAI: timeline to remediation submission, confidence level in re-approval, any production line halt/impact, and export/shipment continuity. This single item will move the stock 2-3%+ and will dominate the call.
2 · US Revenue & Realization Trends
Generics + specialty growth YoY; pricing/volume mix; competitive share trends. US is 40%+ of revenue and the growth engine — softness here signals broader execution risk.
3 · FY27 Guidance — Reconfirmed?
Will management stand by 20-21% EBITDA margin guidance for FY27? Any update on revenue growth expectations or Medtech loss assumptions? This frames the full-year narrative.
4 · Occlutech Integration & Medtech Losses
Q1 will consolidate the first month of Occlutech. Are losses tracking the ₹40-50 Cr annual guidance? Any surprise upside/downside? Monitor cash burn assumptions.
Alkem reports Q1 FY27 on August 14 at an inflection: the FDA compliance issue is now live (OAI status is material), the medtech transition is underway (Occlutech closed), and the core generics + specialty business must prove resilience. The stock, near consensus target (₹5,535) and neutral on technicals (RSI 48), will respond sharply to three data points: (1) credible FDA remediation timelines and confidence, (2) US generics growth holding double-digit pace, and (3) reconfirmed FY27 margin guidance. A clean quarter with transparent FDA commentary could support the Nomura/ICICI upsides; any miss or vague guidance tilts the needle toward Jefferies' downside caution.